Posted by Michael Wonder on 15 Jul 2021
Cystic fibrosis patients upset over recommended restrictive criteria for life saving drug
15 July 2021 - 'By narrowly defining accessibility and continuation criteria CADTH’s recommendation overlooks many of Trikafta’s significant benefits,' says chief scientific officer for CF Canada.
Last month the cystic fibrosis community was relieved and overjoyed when Health Canada announced its approval for the life-saving drug TRIKAFTA for those aged 12 and up with cystic fibrosis and at least one F508del mutation.
